Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - docetaxel, quantity: 10 mg/ml - injection, solution - excipient ingredients: citric acid; polysorbate 80; macrogol 300; ethanol absolute - breast cancer: - for the treatment of patients with locally advanced or metastatic breast cancer. - in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. - in combination with xeloda? (capecitabine) is indicated for the treatment of patients with advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. non-small cell lung cancer: - for the treatment of patients with locally advanced or metastatic non-small cell lung cancer in monotherapy or in combination with platinum derivatives. ovarian cancer: - for the treatment of metastatic carcinoma of the ovary after failure of first-line or subsequent chemotherapy. prostate cancer: - in combination with prednisone or prednisolone is indicated for the treatment of patients with androgen-independent (hormone-refractory) metastatic prostate cancer. squamous cell carcinoma of the head and neck: - indicated as monotherapy in the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after failure of a previous chemotherapy regimen.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - docetaxel, quantity: 10 mg/ml - injection, solution - excipient ingredients: citric acid; polysorbate 80; macrogol 300; ethanol absolute - breast cancer: - for the treatment of patients with locally advanced or metastatic breast cancer. - in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. - in combination with xeloda? (capecitabine) is indicated for the treatment of patients with advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. non-small cell lung cancer: - for the treatment of patients with locally advanced or metastatic non-small cell lung cancer in monotherapy or in combination with platinum derivatives. ovarian cancer: - for the treatment of metastatic carcinoma of the ovary after failure of first-line or subsequent chemotherapy. prostate cancer: - in combination with prednisone or prednisolone is indicated for the treatment of patients with androgen-independent (hormone-refractory) metastatic prostate cancer. squamous cell carcinoma of the head and neck: - indicated as monotherapy in the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after failure of a previous chemotherapy regimen.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - docetaxel, quantity: 10 mg/ml - injection, solution - excipient ingredients: citric acid; polysorbate 80; macrogol 300; ethanol absolute - breast cancer: - for the treatment of patients with locally advanced or metastatic breast cancer. - in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. - in combination with xeloda? (capecitabine) is indicated for the treatment of patients with advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. non-small cell lung cancer: - for the treatment of patients with locally advanced or metastatic non-small cell lung cancer in monotherapy or in combination with platinum derivatives. ovarian cancer: - for the treatment of metastatic carcinoma of the ovary after failure of first-line or subsequent chemotherapy. prostate cancer: - in combination with prednisone or prednisolone is indicated for the treatment of patients with androgen-independent (hormone-refractory) metastatic prostate cancer. squamous cell carcinoma of the head and neck: - indicated as monotherapy in the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after failure of a previous chemotherapy regimen.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - pentostatin, quantity: 10 mg - injection, powder for - excipient ingredients: mannitol; sodium hydroxide; hydrochloric acid - smpc - pentostatin is indicated as single agent therapy in the treatment of adult patients with hairy cell leukaemia. label - nipent is an anticancer medicine used to treat adults with hairy cell leukaemia, a form of cancer affecting lymphocytes (white blood cells important for fighting invading viruses and bacteria)

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - pentostatin, quantity: 10 mg - injection, powder for - excipient ingredients: mannitol; hydrochloric acid; sodium hydroxide - nipent is indicated as single-agent treatment for both untreated and alpha-interferon-refractory hairy cell leukemia patients with active disease as defined by clinically significant anemia,neutropenia, thrombocytopenia, or disease-related symptoms.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 45.54 mg/ml - injection - excipient ingredients: mannitol; sodium acetate trihydrate; water for injections; hydrochloric acid; sodium hydroxide - gemcitabine for injection, usp (gemcitabine hydrochloride) is indicated for the: treatment of patients with locally advanced (nonresectable stage ii or stage iii) or metastatic (stage iv) adenocarcinoma of the pancreas to achieve a clinical benefit response (a composite measure of clinical imporvement). treatment of patients with locally advanced or metastatic non-small lung cancer (nsclc) as either a single agent or in combination with cisplatin. treatment of patients with stage iv (locally advanced or metastatic) transitional cell carcinoma (tcc) of the bladder in combination with cisplatin. treatment, in combination with paclitaxel, of patients with inresectable, locally recurrent or metastatic breast cancer, who have good performance status and have relapsed following adjuvant anthracycline-based chemotherapy.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 45.54 mg/ml - injection - excipient ingredients: mannitol; sodium acetate trihydrate; water for injections; hydrochloric acid; sodium hydroxide - gemcitabine for injection, usp (gemcitabine hydrochloride) is indicated for the: treatment of patients with locally advanced (nonresectable stage ii or stage iii) or metastatic (stage iv) adenocarcinoma of the pancreas to achieve a clinical benefit response (a composite measure of clinical imporvement). treatment of patients with locally advanced or metastatic non-small lung cancer (nsclc) as either a single agent or in combination with cisplatin. treatment of patients with stage iv (locally advanced or metastatic) transitional cell carcinoma (tcc) of the bladder in combination with cisplatin. treatment, in combination with paclitaxel, of patients with inresectable, locally recurrent or metastatic breast cancer, who have good performance status and have relapsed following adjuvant anthracycline-based chemotherapy.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 45.54 mg/ml - injection - excipient ingredients: mannitol; sodium acetate trihydrate; water for injections; hydrochloric acid; sodium hydroxide - gemcitabine for injection, usp (gemcitabine hydrochloride) is indicated for the: treatment of patients with locally advanced (nonresectable stage ii or stage iii) or metastatic (stage iv) adenocarcinoma of the pancreas to achieve a clinical benefit response (a composite measure of clinical imporvement). treatment of patients with locally advanced or metastatic non-small lung cancer (nsclc) as either a single agent or in combination with cisplatin. treatment of patients with stage iv (locally advanced or metastatic) transitional cell carcinoma (tcc) of the bladder in combination with cisplatin. treatment, in combination with paclitaxel, of patients with inresectable, locally recurrent or metastatic breast cancer, who have good performance status and have relapsed following adjuvant anthracycline-based chemotherapy.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 45.54 mg/ml - injection - excipient ingredients: mannitol; sodium acetate trihydrate; water for injections; hydrochloric acid; sodium hydroxide - locally advanced or metastatic bladder cancer in combination with other cytostatic medicinal products. - locally advanced or metastatic breast cancer in combination with paclitaxel in patients experiencing a relapse after adjuvant/neoadjuvant chemotherapy. the preceding chemotherapy should have included an anthracycline unless clinically contraindicated. - locally advanced or metastatic non-small cell lung cancer in combination with other cytostatic medicinal products. palliative treatment of adult patients with locally advanced or metastatic nonsmall cell lung cancer. - locally advanced or metastatic adenocarcinoma of the pancreas in patients who are in good general condition with adequate bone marrow reserves. patients with 5-fluorouracil refractory pancreatic cancer.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - gemcitabine hydrochloride, quantity: 45.54 mg/ml - injection - excipient ingredients: mannitol; sodium acetate trihydrate; water for injections; sodium hydroxide; hydrochloric acid - locally advanced or metastatic bladder cancer in combination with other cytostatic medicinal products. - locally advanced or metastatic breast cancer in combination with paclitaxel in patients experiencing a relapse after adjuvant/neoadjuvant chemotherapy. the preceding chemotherapy should have included an anthracycline unless clinically contraindicated. - locally advanced or metastatic non-small cell lung cancer in combination with other cytostatic medicinal products. palliative treatment of adult patients with locally advanced or metastatic nonsmall cell lung cancer. - locally advanced or metastatic adenocarcinoma of the pancreas in patients who are in good general condition with adequate bone marrow reserves. patients with 5-fluorouracil refractory pancreatic cancer.